QS Investors’s Minerva Neurosciences NERV Stock Holding History

QS Investors’s Portfolio NERV Stock Details NERV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-125	Closed	-$4K	–	1410
2020 Q2	$4K	Hold	125	–	–	﹤0.01%	1626
2020 Q1	$7K	Buy	+125	New	+$7.54K	﹤0.01%	1562

Other funds holding NERV

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

QS Investors's NERV Position: Q3 2020 in Review

QS Investors sold out of Minerva Neurosciences (NERV) in Q3 2020, closing a stake of 125 shares — an estimated $4K sold.

QS Investors first reported a position in NERV in Q1 2020 and held it in 2 quarters. The position peaked at $7K in Q1 2020. 76 funds tracked by Wall St. Rank hold NERV as of Q3 2020.

QS Investors reported no remaining Minerva Neurosciences position as of Q3 2020 after selling out during the quarter.
QS Investors sold 125 Minerva Neurosciences shares in Q3 2020, an estimated $4K.
QS Investors first reported a position in Minerva Neurosciences in Q1 2020 and held it in 2 quarters.
QS Investors's Minerva Neurosciences position peaked at $7K in Q1 2020.
76 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q3 2020.

Based on QS Investors's 13F filing for Q3 2020, filed 12 Nov 2020.